SCHEMBL12835265

SCHEMBL12835265

O=C(O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1C(=O)Nc1cccc(CO)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NHERF1 O14745 2/20 0.50
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
HIF1A Q16665 1/20 0.49
HSD17B10 Q99714 1/20 0.49
CNR2 P34972 1/20 0.47
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
ALOX12 P18054 1/20 0.46
MAPK1 P28482 1/20 0.46
PDK1 Q15118 1/20 0.45
PDK2 Q15119 1/20 0.45
PDK3 Q15120 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12172974 0.88 TAS1R3 (0.55) CYP1A2CYP3A4CYP2D6CYP2C9HIF1A
SCHEMBL12835020 0.82 HSD17B10 (0.50) NHERF1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL12835317 0.81 ALDH1A1 (0.46) NHERF1CNR2NPC1RAB9ASMN1; SMN2
SCHEMBL2761484 0.80 GAA (0.55) CYP1A2CYP3A4CYP2D6CYP2C9HIF1A
SCHEMBL12189490 0.80 MGLL (0.57) CYP1A2CYP3A4CYP2D6CYP2C9HIF1A
SCHEMBL7822944 0.80 MEN1 (0.58) CYP1A2CYP3A4CYP2D6CYP2C9HIF1A
SCHEMBL12189666 0.77 CYP1A2 (0.48) NHERF1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL12172994 0.77 MITF (0.57) CYP1A2CYP3A4CYP2D6CYP2C9HIF1A
SCHEMBL12835340 0.77 HTT (0.61) CYP1A2CYP3A4CYP2D6CYP2C9HIF1A
SCHEMBL20473774 0.76 KCNK3 (0.71) NPC1RAB9ASMN1; SMN2L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150031663-A1 PHTHALANILATE COMPOUNDS AND METHODS OF USE UNIVERSITY OF NOTRE DAME DU LAC (US) 2015-01-29 US disclosed
US-8859620-B2 Phthalanilate compounds and methods of use UNIVERSITY OF NOTRE DAME DU LAC (US) 2014-10-14 US disclosed
WO-2011026107-A1 PHTHALANILATE COMPOUNDS AND METHODS OF USE UNIVERSITY OF NOTRE DAME DU LAC (US) 2011-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031663-A1 PHTHALANILATE COMPOUNDS AND METHODS OF USE MPO, ALPI, NQO1 NHERF1 1126/4885CYP1A2 916/4885CYP3A4 576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.